These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 9194500)

  • 1. Cytoskeletal and morphological changes associated with the specific suppression of the epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid carcinoma.
    Nelson JM; Fry DW
    Exp Cell Res; 1997 Jun; 233(2):383-90. PubMed ID: 9194500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
    Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adhesion, actin cytoskeleton organisation and the spreading of colon adenocarcinoma cells induced by EGF are mediated by alpha2beta1 integrin low clustering through focal adhesion kinase.
    Pichard V; Honoré S; Kovacic H; Li C; Prevôt C; Briand C; Rognoni JB
    Histochem Cell Biol; 2001 Oct; 116(4):337-48. PubMed ID: 11702192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the epidermal growth factor receptor associated with cytoskeletons of A431 cells.
    Roy LM; Gittinger CK; Landreth GE
    J Cell Physiol; 1989 Aug; 140(2):295-304. PubMed ID: 2745564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor.
    Brunton VG; Carlin S; Workman P
    Anticancer Drug Des; 1994 Aug; 9(4):311-29. PubMed ID: 7916899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of cytotoxic effect of epidermal growth factor (EGF) on EGF receptor overexpressing cells is associated with attenuation of EGF receptor tyrosine kinase activity.
    Gardner DP; Shimizu N
    J Cell Physiol; 1994 Feb; 158(2):245-55. PubMed ID: 8106561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient.
    Gross ME; Zorbas MA; Danels YJ; Garcia R; Gallick GE; Olive M; Brattain MG; Boman BM; Yeoman LC
    Cancer Res; 1991 Mar; 51(5):1452-9. PubMed ID: 1847663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
    Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sporostatin, a novel and specific inhibitor of EGF receptor kinase.
    Murakami Y; Ishii A; Mizuno S; Yaginuma S; Uehara Y
    Anticancer Res; 1999; 19(5B):4145-9. PubMed ID: 10628366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of epidermal growth factor-stimulated EGF receptor tyrosine kinase activity in A431 human epidermoid carcinoma cells by polyamines.
    Faaland CA; Laskin JD; Thomas TJ
    Cell Growth Differ; 1995 Feb; 6(2):115-21. PubMed ID: 7756170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
    Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
    Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
    Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868.
    Simpson BJ; Bartlett JM; Macleod KG; Rabiasz G; Miller EP; Rae AL; Gordge P; Leake RE; Miller WR; Smyth J; Langdon SP
    Br J Cancer; 1999 Mar; 79(7-8):1098-103. PubMed ID: 10098742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation.
    Donato NJ; Ince C; Rosenblum MG; Gallick GE
    J Cell Biochem; 1989 Nov; 41(3):139-57. PubMed ID: 2482293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
    Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
    J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.